Ocular Gene Therapy
Early positive data reported for geographic atrophy modifier gene therapy
OCU410, a single-dose modifier gene therapy, demonstrated positive preliminary outcomes for the treatment of geographic atrophy in a phase 1/2 clinical trial, according to a press release from Ocugen.
Adverum reports positive 52-week, 4-year data for wet AMD gene therapy
Adverum Biotechnologies reported positive 52-week data from the phase 2 LUNA trial as well as long-term follow-up results from the OPTIC trial of Ixo-vec in patients with wet age-related macular degeneration.
VIDEO: Single ABBV-RGX-314 treatment stabilizes diabetic retinopathy at 1 year
INDIANAPOLIS — A single in-office treatment of ABBV-RGX-314 was well-tolerated and improved severity of diabetic retinopathy, according to 1-year study results presented at Academy 2024.
VIDEO: Bilateral ABBV-RGX-314 shows positive outcomes in wet AMD
CHICAGO — In this Healio Video Perspective from Retina Subspecialty Day at the AAO meeting, Arshad M. Khanani, MD, MA, FASRS, discusses bilateral ABBV-RGX-314 gene therapy for neovascular age-related macular degeneration.
VIDEO: Optogenetic therapy trial in retinitis pigmentosa meets safety, efficacy endpoints
CHICAGO — In this Healio Video Perspective from the AAO meeting, Allen C. Ho, MD, of Wills Eye Hospital shares promising results of a phase 2b/3 trial investigating MCO-010 optogenetic therapy for the treatment of retinitis pigmentosa.
VIDEO: Intravitreally administered 4D-150 shows 90% reduction in wet AMD treatment burden
BARCELONA, Spain — In this Healio Video Perspective from the Euretina congress, Anat Loewenstein, MD, MHA, speaks about 4D-150, a novel intravitreally administered gene therapy for wet age-related macular degeneration.
VIDEO: Ixo-vec for neovascular AMD shows treatment burden reduction at 26 weeks
In this Healio Video Perspective from the Retina Society meeting, Mark R. Barakat, MD, discusses the 26-week interim analysis for Ixo-vec for the treatment of neovascular age-related macular degeneration.
VIDEO: Optogenetic therapy shows promise for inherited retinal dystrophies
BARCELONA, Spain — In this Healio Video Perspective from the Euretina congress, Paulo-Eduardo Stanga, MD, explains the principles and mechanisms of action of optogenetic gene therapy.
FDA grants rare pediatric disease designation for Leber congenital amaurosis gene therapy
Opus Genetics received rare pediatric disease designation from the FDA for its ocular gene therapy designed to treat patients with a form of Leber congenital amaurosis, according to a press release.
FDA roundup: Recent news in ophthalmology
Healio’s recent FDA news in ophthalmology includes the approval of Enzeevu for neovascular age-related macular degeneration and a rare pediatric disease designation for an X-linked retinoschisis candidate.